Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis

Bjørnhart, Birgitte; Hansen, Karin Holmskov; Asmussen, Jon Thor; Jørgensen, Trine Lembrecht; Herrstedt, Jørn; Schytte, Tine

doi:10.3390/cancers14071682

Cited by 3 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using the criteria outlined in the Methods section, Frontiers in Pharmacology frontiersin.org 66 publications were evaluated by browsing the full set of studies; however, some did not provide sufficient outcome data from the two approaches. Finally, 54 articles (Ahn et al, 2019;Akamatsu et al, 2020;Aso et al, 2020;Baldini et al, 2020;Berner et al, 2019;Bjørnhart et al, 2019;Bouhlel et al, 2020;Campredon et al, 2019;Cortellini et al, 2019;Chen et al, 2021;Chmielewska et al, 2021;Cui et al, 2020;Cortijo-FIGURE 4 Sub-group analysis of OS between IrAEs and ICI efficacy with types of irAEs.…”

Section: Overview Of the Literature Searchmentioning

confidence: 99%

Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis

Lin,

Liu,

Chen

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: Our study aimed to identify potential correlations between anti-tumor efficacy and immune-related adverse events (irAEs) in non-small-cell lung cancer (NSCLC).Methods: We conducted a comprehensive search of online electronic databases up to March 2023 to identify any correlations between irAEs and immune checkpoint inhibitor (ICI) efficacy in NSCLC. We used meta-analysis RevMan 5.3 software to calculate pooled results.Results: Our meta-analysis of 54 studies revealed that patients who experienced irAEs achieved a significantly higher objective response rate (p < 0.00001) and longer progression-free survival (PFS) (p < 0.00001) and overall survival (OS) (p < 0.00001) than those who did not experience irAEs. Additionally, patients with ≥2 irAEs had better PFS, whereas no significant difference was observed between patients with or without squamous cell carcinoma. Subgroup analysis of irAE types indicated that irAEs (thyroid dysfunction and gastrointestinal, skin, or endocrine irAEs) were associated with better PFS and OS. However, no significant differences were observed between patients with pneumonitis or hepatobiliary irAEs.Conclusion: Our study showed that the occurrence of irAEs was a strong predictor of survival efficacy in patients with NSCLC treated with ICIs. Specifically, patients with ≥2 irAEs and those with thyroid dysfunction and gastrointestinal, skin, or endocrine irAEs achieved a better survival benefit.Systematic Review Registration: Website: https://www.crd.york.ac.uk/prospero/, Identifier: CRD42023421690

show abstract

Section: Overview Of the Literature Searchmentioning

confidence: 99%

Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis

Lin,

Liu,

Chen

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Immunotherapy: an emerging modality to checkmate brain metastasis

et al. 2023

View full text Add to dashboard Cite

The diagnosis of brain metastasis (BrM) has historically been a dooming diagnosis that is nothing less than a death sentence, with few treatment options for palliation or prolonging life. Among the few treatment options available, brain radiotherapy (RT) and surgical resection have been the backbone of therapy. Within the past couple of years, immunotherapy (IT), alone and in combination with traditional treatments, has emerged as a reckoning force to combat the spread of BrM and shrink tumor burden. This review compiles recent reports describing the potential role of IT in the treatment of BrM in various cancers. It also examines the impact of the tumor microenvironment of BrM on regulating the spread of cancer and the role IT can play in mitigating that spread. Lastly, this review also focuses on the future of IT and new clinical trials pushing the boundaries of IT in BrM.

show abstract

Health-related Quality of Life in Patients with Melanoma Brain Metastases Treated with Immunotherapy

et al. 2023

View full text Add to dashboard Cite

Aims: To describe the health-related quality of life (HRQoL) of melanoma brain metastasis (MBM) patients throughout the first 18 weeks of ipilimumab–nivolumab or nivolumab treatment. Materials & methods: HRQoL data (European Organisation for Research and Treatment of Cancer's Core Quality of Life Questionnaire, additional Brain Neoplasm Module, and EuroQol 5-Dimension 5-Level Questionnaire) were collected as a secondary outcome of the Anti-PD1 Brain Collaboration phase II trial. Mixed linear modeling assessed changes over time, whereas the Kaplan–Meier method was used to determine median time to first deterioration. Results: Asymptomatic MBM patients treated with ipilimumab–nivolumab (n = 33) or nivolumab (n = 24) maintained baseline HRQoL. MBM patients with symptoms or leptomeningeal/progressive disease treated with nivolumab (n = 14) reported a statistically significant trend toward improvement. Conclusion: MBM patients treated with either ipilimumab–nivolumab or nivolumab did not report a significant deterioration in HRQoL within 18 weeks of treatment initiation. Clinical trial registration: NCT02374242 ( ClinicalTrials.gov )

show abstract

Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis

Cited by 3 publications

References 53 publications

Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis

Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis

Immunotherapy: an emerging modality to checkmate brain metastasis

Health-related Quality of Life in Patients with Melanoma Brain Metastases Treated with Immunotherapy

Contact Info

Product

Resources

About